top of page
News
A new drug targeting the genetic cause of a rare form of motor neurone disease (MND) has shown encouraging results in early research supported by the National Institute for Health and Care Reseaerch (NIHR).
The phase 1-2 study, published in the New England Journal of Medicine, has shown that the new investigational drug tofersen is safe and well tolerated in people with a genetic form of MND.
bottom of page